Apollo endosurgery announces two important milestones in the advancement of endoscopic procedures for patients living with obesity

Merit trial selected as 2022 top story in gastroenterology and asmbs adds apollo systems to list of approved bariatric devices austin, tx / accesswire / december 13, 2022 / apollo endosurgery, inc. ("apollo") (nasdaq:apen), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the merit trial, published in the lancet earlier this year(1), was selected as 2022 top story in gastroenterology. (2) additionally, the american society for metabolic and bariatric surgery (asmbs) formally added four apollo systems to its list of fda approved bariatric devices on december 5.
APEN Ratings Summary
APEN Quant Ranking